Furthermore, serum TRAIL levels hold clinical significance, as evidenced in a study involving eighteen patients with refractory prostate cancer, where higher serum TRAIL levels at nine months correlated with improved clinical outcomes (75). This evidence concerns the gene TNFSF10 and prostate cancer.